FIELD: biochemistry.
SUBSTANCE: invention is related to a human antibody molecule that binds in an immune-specific way to human CXCR2. A nucleic acid encoding said antibody; a vector or cell containing said nucleic acid; a pharmaceutical composition containing said antibody, are also disclosed. Method of treatment using said antibody; use of said antibody to produce a medicinal product; a method of blocking neutrophil chemotaxis using said antibody; a method of blocking CXCR2 signalling in response to CXCL1 and/or CXCL5 in cells expressing CXCR2 signalling, are disclosed.
EFFECT: invention makes it possible to effectively treat diseases such as neutrophilia of the respiratory tract or acute pneumonia.
25 cl, 12 ex, 19 tbl, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| NEW VERSIONS OF HYALURONIDASE WITH IMPROVED STABILITY AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2021 |
|
RU2811464C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
